Skip to content. | Skip to navigation


Personal tools

Kelsie L. Thu, PhD

Postdoctoral research associate and Graduate student. Currently Postdoctoral fellow with Dr. Tak Mak at PMCC.

KelsieThu 


kthu@bccrc.ca  675 West 10th Avenue, Vancouver, B.C., V5Z 1L3, Canada 

| BCCA | BCCRC | Integrative Oncology | Cancer Genetics | Wan Lam Lab | Kelsie Thu |


Training

  • PhD (Interdisciplinary Oncology), University of British Columbia, 2013

  • BSc (Biology), Simon Fraser University, 2007

  • Health and Fitness Certificate (Kinesiology), Simon Fraser University, 2007


Research Interests

Topics of interest: 

  • Cancer biology, genetics, epigenetics, metabolism, immune evasion, chemoprevention

Topics studied: 

  • Lung cancer biology - discovery of genes and pathways contributing to tumour biology and discovery of potential therapeutic targets
  • Lung cancer in never smokers - comparison of molecular mechanisms in current and never smokers and identification of genes and pathways involved in never smoker tumourigenesis
  • Genetic and epigenetic mechanisms of gene disruption - integrative genomic analysis
  • Pancreatic cancer genetics - tumour suppressor gene discovery in pancreatic ductal adenocarcinoma

Scholarships and Awards

Academic

Terry Fox Research Institute, 5th Annual Meeting Trainee Travel Award (2014)
BC Cancer Agency Lloyd Skarsgard Research Excellence Prize (2013)
Canadian Cancer Society Research Institute Travel Award (2013)
UBC Faculty of Graduate Studies Travel Award (2013)
UBC Bioinformatics & Oncology Research Day, Gold Poster Award (2013)
Canadian Bioinformatics Workshop MITACs Travel and Registration Award (2012)
CIHR Institute of Cancer Research Travel Award (2011)
UBC Bioinformatics & Oncology Research Day, Poster Award (2011)
International Association for the Study of Lung Cancer Young Investigator Award (2011)
Betty Rice Award, Lung Cancer Research (2011)
AACR Scholar-in-Training Award (2010)
Vanier Canada Graduate Scholarship (2010-2013)
UBC Four Year Doctoral Fellowship (2009)
CIHR Frederick Banting and Charles Best Canada Graduate Scholarship - Master's Award (2009)
Interdisciplinary Oncology Program Travel Awards (2009, 2010, 2013)
Dr. Don Rix Best Student Abstract Award, World Biomarker Conference (2009)
UBC Graduate Entrance Scholarship (2008)
BCCA Annual Cancer Conference Poster Competition Award for Basic Science Research (2008)
Interdisciplinary Oncology Recruitment Training Incentive Award, UBC (2008)
NSERC Canada Undergraduate Student Research Award (2006)
Dean’s Honour Roll at SFU (2004, 2005, 2006, 2007)
SFU Undergraduate Open Academic Scholarship (2005, 2006, 2007)
SFU Top Ten Scholar Athlete (2005, 2007) and Top Scholar Athlete (2006)
SFU Tadeusz Specht Memorial Entrance Scholarship (2002)
Miller Thompson Scholarship (2002)
Passport to Education (2002)

Athletic

Mayko MacLeod Memorial Scholarship, SFU Basketball (2007)
SFU Women’s Basketball Most Inspirational Player Award (2006)
Canadian Interuniversity Sport Women’s Basketball National Champions (2005, 2007)
SFU Clan Athletics President’s Team Award (2005, 2007)
SFU Athletics Basketball Scholarship (2002-2007)
Canadian Interuniversity Sport Academic All-Canadian (2004, 2005, 2006, 2007)


Publications

First and co-first authorships are denoted by an underline
* indicates publications for which I am corresponding author

  1. Marshall EA, Ng KW, Anderson C, Hubaux R, Thu KL, Lam WL, Martinez VD (2015) Gene expression analysis of microtubule affinity-regulating kinase 2 in non-small cell lung cancer. Genomics Data. Accepted for publication.

  2. Hubaux R, Thu KL, Vucic EA, Pikor LA, Kung SHY, Martinez VD, Mosslemi M, Becker-Santos DD, Gazdar AF, Lam S, Lam WL (2015) Microtubule affinity-regulating kinase 2 contributes to cisplatin sensitivity through modulation of the DNA damage response in non-small cell lung cancer. International Journal of Cancer. In press. [PMID:25907283]

  3. Martinez VD, Vucic EA, Thu KL, Hubaux R, Enfield KSS, Pikor LA, Becker-Santos DD, Brown CJ, Lam S, Lam WL (2015) Unique somatic and malignant expression patterns implicate PIWI-interacting RNAs in cancer-type specific biology. Scientific Reports. 5:10423, 1-17. [PMID:26013764]

  4. Radulovich N, Leung L, Ibrahimov E, Navab R, Sakashita S, Lockwood WW, Thu KL, Fedeshyn Y, Moffat J, Lam WL, Tsao MS (2015) Coiled-coil domain containing 68 (CCDC68) demonstrates a tumor-suppressive role in pancreatic ductal adenocarcinoma. Oncogene. In press. [PMID:25381825]

  5. Martinez VD, Vucic EA, Thu KL, Pikor LA, Lam S, Lam WL (2015) Disruption of KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex components by multiple genetic mechanisms is associated with poor prognosis in head and neck cancer. Head and Neck 37(5):727-3. [PMID: 24596130]

  6. Clermont PL, Lin D, Crea F, Wu R, Xue H, Wang Y, Thu KL, Lam WL, Wang YZ, Helgason CD (2015) Polycomb-mediated silencing in neuroendocrine prostate cancer. Clinical Epigenetics 7(1):40, 1-13. [PMID:25859291]

  7. Thu KL, Radulovich N, Becker-Santos DD, Pikor LA, Pusic A, Lockwood WW, Lam WL, Tsao MS (2014) SOX15 is a candidate tumor suppressor in pancreatic cancer with a role in Wnt/β-catenin signaling. Oncogene. 33(3):279-88. [PMID: 23318427]

  8. Thu KL, Becker-Santos DD, Radulovich N, Pikor LA, Lam WL, Tsao MS (2014) SOX15 and other SOX family members are important mediators of tumorigenesis in multiple cancer types. Oncoscience 1(5):326-35. [PMID:25594027]

  9. Hubaux R, Thu KL, Lam WL (2014) Re: WNT signaling pathway in non-small cell lung cancer. JNCI-Journal of the National Cancer Institute 106 (8): dju188. [PMID:25082336]

  10. Vucic EA, Chari R, Thu KL, Wilson IM, Cotton AM, Kennett JY, Zhang M, Lonergan KM, Steiling K, Brown CJ, McWilliams A, Ohtani K, Lenburg ME, Sin DD, Spira A, MacAulay CE, Lam S, Lam WL (2014) DNA methylation is globally disrupted and associated with expression changes in chronic obstructive pulmonary disease small airways.  American Journal of Respiratory Cell Molecular Biology 50(5):912-22. [PMID: 24298892]

  11. Wilson IM, Vucic EA, Enfield KSS, Thu KL, Zhang Y-A, Chari R, Lockwood WW, Radulovich N, Starczynowski DT, Banáth JP, Zhang M, Pusic A, Fuller M, Lonergan KM, Rowbotham D, Yee J, English JC, Buys TPH, Selamat SA, Laird-Offinga I, Liu P, Anderson M, You M, Tsao-MS, Brown CJ, Bennewith KL, MacAulay CE, Karsan A, Gazdar AF, Lam S, Lam WL (2014) EYA4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk. Oncogene33(36):4464-7. [PMID: 24096489]

  12. Clermont PL, Sun L, Crea F, Thu KL, Zhang A, Parolia A, Lam WL, Helgason CD (2014) Genotranscriptomic meta-analysis of the Polycomb gene CBX2 in human cancers: initial evidence of an oncogenic role. British Journal of Cancer. 111(8):1663-72. [PMID:25225902]

  13. Rowbotham D, Enfield KSS, Martinez VD, Thu KL, Vucic EA, Stewart GL,  Bennewith KL, Lam WL (2014) Multiple components of the VHL tumor suppressor complex are frequently affected by DNA copy number losses in pheochromocytoma.  International Journal of Endocrinology. 2014: 546347, 1-9. [PMID:25298778]

  14. Martinez VD, Vucic EA, Thu KL, Pikor LA, Hubaux R, Lam WL (2014) Unique pattern of component gene disruption in the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in serous ovarian cancer. BioMed Research International (formerly Journal of Biomedicine and Biotechnology) 2014:159459, 1-10. [PMID: 25114896]

  15. Vucic EA, Thu KL, Pikor LA, Enfield KS, Yee J, English JC, MacAulay CE, Lam S, Jurisica I, Lam WL (2014). Smoking status impacts microRNA mediated prognosis and lung adenocarcinoma biology. BMC Cancer 14:778, 1-14. [PMID:25342220]

  16. Coe BP, Thu KL*, Aviel-Ronen S, Vucic EA, Gazdar A, Lam S, Tsao MS, Lam WL (2013) Genomic deregulation of the Rb/E2F leads to activation of the oncogene EZH2 in small cell lung cancer. PLoS ONE 8(8):e71670, 1-8. [PMID: 23967231]

  17. Martinez VD, Thu KL, Vucic EA, Hubaux R, Adonis M, Gil L, Ling V, MacAulay C, Lam S, Lam WL (2013) Whole genome sequencing analysis identifies a distinctive mutational spectrum in an arsenic-related lung tumor. Journal of Thoracic Oncology. 8:1451-5. [PMID: 24128716]

  18. Hubaux R, Thu KL, Coe BP, MacAulay C, Lam S, Lam WL (2013) EZH2 promotes E2F driven SCLC tumorigenesis through modulation of apoptosis and cell cycle regulation. Journal of Thoracic Oncology 8:1102-6. [PMID: 23857401]

  19. Hubaux R, Thu KL, Lam WL, Alex A (2013) In response: Do mutations of the enhancer of zeste homolog 2 gene exist in small-cell lung cancer? Journal of Thoracic Oncology 8:e103-4. [PMID: 24128723]

  20. Pikor LA, Lockwood WW, Thu KL, Vucic EA, Chari R, Gazdar AF, Lam S, Lam WL (2013) YEATS4 is a novel oncogene amplified in non-small cell lung cancer that regulates the p53 pathway. Cancer Research 73(24):7301-12. [PMID: 24170126].

  21. Pikor LA, Thu KL, Vucic EA, Lam WL (2013) The detection and implication of genome instability in cancer. Cancer Metastasis Reviews 32:341-52. [PMID: 23633034].

  22. Shien K, Toyooka S, Yamamoto H, Soh J, Jida M, Thu KL, Hashida S, Maki Y, Ichihara E, Asano H, Tsukuda K, Takigawa N, Kiura K, Gazdar AF, Lam WL, Miyoshi S. (2013) Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Research 73:3051-61 [PMID:23542356]

  23. Martinez VD, Vucic EA, Pikor LA, Thu KL, Hubaux R, Lam WL (2013) Frequent concerted genetic mechanisms disrupt multiple components of the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in thyroid cancer. Molecular Cancer 12:124, 1-6. [PMID: 24138990]

  24. Tam KW, Zhang W, Soh J, Stastny V, Chen M, Sun H, Thu KL, Rios JJ, Yang C, Marconett CN, Selamat SA, Laird-Offringa IA, Taguchi A, Hanash S, Shames D, Ma X, Zhang MQ, Lam WL, Gazdar AF, (2013) CDKN2A/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non-small cell lung cancer. Journal of Thoracic Oncology 8:1378-88 [PMID: 24077454]

  25. Vucic EA, Thu KL, Robison K, Rybaczyk LA, Chari R, Alvarez CE, Lam WL (2012) Translating cancer 'omics' to improved outcomes. Genome Research. 22:188-195.

  26. Lockwood WW, Thu KL, Lin L, Pikor LA, Chari R, Lam WL, Beer DG (2012) Integrative genomics identified RFC3 as an amplified candidate oncogene in esophageal adenocarcinoma. Clinical Cancer Research.18(7):1936-46.

  27. Thu KL*, Vucic EA, Chari R, Zhang W, Lockwood WW, English JC, Fu R, Wang P, Feng Z, MacAulay CE, Gazdar AF, Lam S, Lam WL (2012)  Lung adenocarcinomas of never smokers and smokers are genomically distinct.  PLoS ONE. 7(3):e33003, 1-10.

  28. Lockwood WW, Wilson IM, Coe BP, Chari R, Pikor LA, Thu KL, Yee J, English J, Murray N, Tsao MS, Minna J, Gazdar AF, MacAulay CE, Lam S, Lam WL (2012)  Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. PLoS ONE. 7(5):e37775, 1-18.

  29. Thu KL*, Chari R, Lockwood WW, Lam S, Lam WL (2011) miR-101 DNA copy loss is a prominent subtype specific event in lung cancer.  Journal of Thoracic Oncology. 6:1594-1598.

  30. Thu KL*, Pikor LA, Chari R, Wilson IM, MacAulay CE, English JC, Tsao MS, Gazdar AF, Lam S, Lam WL, Lockwood WW (2011) Genetic disruption of KEAP1/CUL3 E3 ubiquitin ligase complex components is a key mechanism for NF-kappaB pathway activation in lung cancer. Journal of Thoracic Oncology. 6:1521-1529.

  31. Thu KL*, Pikor L, Kennett J, Alvarez C, Lam WL (2010) Methylation analysis by DNA immunoprecipitation.  Journal of Cellular Physiology.  222(3):5 22-31.

  32. Chari R, Thu KL, Wilson IM, Lockwood WW, Lonergan KM, Coe BP, Malloff CA, Gazdar AF, Lam S, Garnis C, MacAulay CE, Alvarez CE, Lam WL (2010) Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer.  Cancer and Metastasis Reviews. 29(1):73-93.

  33. Vucic EA, Thu KL, Williams AC, Lam WL, Coe BP (2010) Copy number variations in the human genome and strategies for analysis.  Methods in Molecular Biology. 628: 103-117.

  34. Lockwood WW, Chari R, Coe BP, Thu KL, Garnis C, Malloff CA, Campbell J, Williams AC, Hwang D, Buys TPH, Yee J, English JC, MacAulay C, Tsao MS, Gazdar AF, Minna JD, Lam S, Lam WL (2010) Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma. PLoS Medicine 7(7): e1000315, 1-14.

  35. Thu KL, Vucic EA, Kennett JY, Heryet C, Brown CJ, Lam WL, Wilson IM (2009) Methylated DNA immunoprecipitation.  Journal of Visualized Experiments 23. pii: 935.

  36. Lam K, Thu K, Moore M, Gries G (2009) Bacteria on house fly eggs, Musca domestica, suppress fungal growth in chicken manure through nutrient depletion or antifungal metabolites.  Naturwissenschaften. 96(9): 1127-1132.

  37. Thu KL*, Lam WL, Coe BP. (2009) The emerging role of copy number variation in cancer. Cell Science.  6(2):98, 1-23.


Selected Abstracts and Presentations

Number published at international conferences: 32
Number published at local and national conferences: 27

  1. Thu KL, Hubaux R, Lam S, Lam WL (2014). Disruption of the endocannabinoid system is prominent in lung adenocarcinoma and associated with poor patient survival. Metabolism, Diet and Disease 2014: Cancer and metabolism BioMed Central Conference. Washington DC, USA.
  2. Thu KL, Vucic EA, Pikor LA, Lam S, Lam WL (2014). Prominently disrupted genes in never smoker lung adenocarcinoma are involved in pro-tumourigenic, immune, inflammatory, and metabolic cellular networks. Terry Fox Research Institute 5th Annual Scientific Meeting, Montreal, QC, Canada.
  3. Thu KL, Mosslemi M, Vucic EA, Pikor LA, Zhang W, Selamat S, Laird-Offringa I, Gazdar AF, Ng R, English JC , Lam S, Macaulay CE, Lam WL (2013) Differential pathway disruption in lung adenocarcinomas from current and never smokers – A multi-omics data integration analysis. World Conference on Lung Cancer. Sydney, Australia. Abstract No # 1072.
  4. Thu KL, Mosslemi M, Pikor LA, Vucic EA, Zhang W, Selamat SA, Laird-Offringa IA, Gazdar AF, Lam S, MacAulay CA, Lam WL (2013). Development of an integrative genomics algorithm to investigate differences in the molecular mechanisms contributing to lung adenocarcinoma of smokers and never smokers. ATS 2013 International Conference, Philadelphia, USA.
  5. Thu KL, Coe BP, Vucic EA, Aviel-Ronen S, MacAulay C, Tsao MS, Lam S, Lam WL (2013). Deregulation of the E2F/RB pathway is associated with activation of EZH2 in small cell lung cancer. Bioinformatics and Oncology Retreat, Vancouver, BC. Gold poster award.
  6. Thu KL, Hubaux R, Aviel-Ronen S, MacAulay C, Tsao MS, Lam S, Lam WL, Coe BP (2012). Genomic alteration of E2F/Rb activates EZH2 in small cell lung cancer. AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy, and Personalized Medicine. San Diego, California. Abstract A29.
  7. Thu KL, Mosslemi M, Pikor LA, Vucic EA, Zhang W, Selamat SA, Laird-Offringa IA, Gazdar AF, Lam S, MacAulay CA, Lam WL (2012). Pathway profiles of lung adenocarcinoma in smokers and never smokers. Mechanisms & Models of Cancer. Cold Spring Harbor, New York.
  8. Thu KL, Chari R, Zhang W, MacAulay C, Gazdar AF, Lam S, Lam WL (2011).  Lung adenocarcinoma genomes of current and never smokers are genetically distinct.  Bioinformatics and Oncology Retreat, Vancouver BC.  Abstract 32.
  9. Thu KL, Becker D, Chari R, Zhang W, MacAulay C, Gazdar AF, Lam S, Lam WL (2011) Lung adenocarcinoma genomes of never smokers exhibit a greater extent of genomic instability than those of smokers.  World Conference on Lung Cancer. Amsterdam, Netherlands. Abstract No # 3688. Invited talk.
  10. Thu KL, Becker D, Radulovich R, Lockwood WW, Tsao MS, Lam WL (2011). SOX15 is a novel tumour suppressor gene frequently inactivated by two-hits in pancreatic cancer. British Columbia Cancer Agency Annual Conference. Vancouver, BC. Abstract 2A.
  11. Thu KL, Chari R, Zhang W, MacAulay CE, Gazdar AF, Lam S, Lam WL (2010).  Lung cancer genomes of smokers and never smokers harbor differential regions of copy number alteration.  AACR Frontiers in Cancer Prevention 2010.  Philadelphia, Pennsylvania.  Abstract #A15.
  12. Thu KL, Chari R, Lam WL (2010) miR-101, a candidate tumour suppressor inactivated by DNA deletion in non-small cell lung cancer. 2010 Canadian Student Health Research Forum, Winnipeg, MB. Abstract/Poster 192.
  13. Thu KL, Lockwood WW, Williams AC, Lam A, Lam WL (2009) Integrative genetic analysis reveals novel amplicons in pancreatic cancer. AACR Annual Meeting 2009.  Denver, Colorado.  Abstract #1426.
  14. Thu KL, Lockwood WW, Chari R, Coe BP, MacAulay C, Girard L, Gazdar AF, Minna JD, Lam S, Lam WL (2009)  Identification of candidate tumour suppressor genes in lung cancer by integrative genomic analyses.  Pathology Day, University of British Columbia, Vancouver, BC. Abstract #32.
  15. Thu K, Lockwood WW, Williams AC, Lam A, Lam WL (2009) Integrative genomic analyses reveal potential oncogene loci in pancreatic cancer. Global Biomarker Conference 2009. Vancouver, BC. Dr. Don Rix best student abstract award. (no abstract number given) Invited talk.
  16. Thu KL, Lockwood WW, Chari R, Coe BP, MacAulay C, Girard L, Gazdar AF, Minna JD, Lam S, Lam WL (2009) Integrating genome wide DNA copy number and mRNA expression analyses identifies new candidate tumour suppressor genes in lung cancer.  World Conference on Lung Cancer.  San Francisco, California.  Abstract # B3.3  Invited talk.
  17. Thu KL, Lockwood WW, Chari R, Coe BP, MacAulay C, Girard L, Gazdar AF, Minna JD, Lam S, Lam WL (2009) Candidate tumour suppressor genes inactivated by DNA deletion in lung cancer.  COMBIO 2009.  Christchurch, New Zealand. Abstract #B50.
  18. Thu KL, Campbell J, Garnis C, Coe BP, Lam WL, MacAulay C, Lam S (2008) Malignancy associated changes induced in normal cells by lung cancer.  British Columbia Cancer Agency Annual Conference. Vancouver, BC.  Basic science best poster presentation award.  Abstract #14-D
  19. Thu KL, Campbell J, Garnis C, Coe BP, Lam WL, MacAulay C, Lam S (2008) Gene expression analysis of malignancy associated changes in normal bronchial epithelium.  AACR Frontiers in Cancer Prevention Conference.  Washington, DC.  Abstract #A10. 

 Invited Talks

  1. British Columbia Cancer Agency Lloyd Skarsgard Research Excellence Award seminar. British Columbia Cancer Agency Research Centre 2014. Vancouver, Canada.
  2. A multi-platform approach to biomarker discovery in lung cancers in never smokers -- BC Cancer Agency Update.  Canary Foundation Lung Team Meeting 2012.  MD Anderson, University of Texas. Houston, Texas.
  3. A multi-platform approach to biomarker discovery in lung cancers in never smokers -- BC Cancer Agency Year 3 Progress.  Canary Foundation Meeting 2012.  Canary Center, Stanford University. Palo Alto, California.
  4. A multi-platform approach to biomarker discovery in lung cancers in never smokers -- BC Cancer Agency Year 2 Progress.  Canary Foundation Meeting 2011.  Canary Center, Stanford University. Palo Alto, California.
  5. Lung adenocarcinoma genomes of never smokers exhibit a greater extent of genomic instability than those of smokers. World Conference on Lung Cancer 2011. Amsterdam, Netherlands.
  6. Lung cancer in never smokers.  UBC Respiratory Seminar Series 2011. Vancouver, BC.
  7. Genomic alterations in never smokers with adenocarcinoma of the lung.  Lung Tumor Group Research Day 2011. Vancouver, BC.
  8. A multi-platform approach to biomarker discovery in lung cancers in never smokers -- BC Cancer Agency Year 1 Progress.  Canary Foundation Meeting 2010.  Canary Center, Stanford University. Palo Alto, California.
  9. Integrating genome wide DNA copy number and mRNA expression analyses identifies new candidate tumour suppressor genes in lung cancer.  World Conference on Lung Cancer 2009.  San Francisco, California.
  10. Integrative genomic analyses reveal potential oncogene loci in pancreatic cancer. Global Biomarker Conference 2009. Vancouver, BC.

Links

| BCCA | BCCRC | Integrative Oncology | Cancer Genetics | Wan Lam Lab | Kelsie Thu |